Abstract
Colorectal liver metastasis (CRLM) is a treatable condition, with the prospect of cure in some patients in whom surgery and multimodal therapy is possible 1–3. Historical boundaries to liver resection (such as number, size, and location of CRLMs) have been replaced by poor cancer biology as the principal prognostic factor 4–7. Before liver resection, surgeons now assess what will stay (future liver remnant), rather than contemplating what will go (tumour burden), to determine surgical operability or need for preoperative modifications (for example, portal vein embolization or associating liver partition and portal vein ligation for staged hepatectomy) to increase resectability and prevent liver failure 3. Further technical advances are being introduced, such as simultaneous portal vein and liver vein embolization (liver vein deprivation) 8, and are now being assessed in ongoing prospective randomized trials. Systemic cytotoxic therapy (such as oxaliplatin or irinotecan), biological agents (bevacizumab or cetuximab), and immune checkpoint inhibitors have expanded systemic treatment options such that tumours are deemed suitable for resection 9. Unfortunately, the vast majority (70–80 per cent) experience recurrence after hepatectomy, most often in the liver (regrowth of persistent CRLMs) 10. Repeat liver resection with or without ablation techniques 2, hepatic artery infusion 11, and selective internal radiation therapy 12 or drug delivery are all possible for disease control. There are reports of improved progression-free survival but there may be no gain in overall survival, so the selection of patients is key to limiting what could be non-effective or even futile interventions.

This publication has 20 references indexed in Scilit: